APOKYN
LOE Approachingapomorphine hydrochloride
NDASUBCUTANEOUSINJECTABLEPriority Review
Approved
Apr 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Mechanism of Action
non-ergoline dopamine agonist with high in vitro binding affinity for the dopamine D 4 receptor, and moderate affinity for the dopamine D 2 , D 3 , and D 5 , and adrenergic α 1 D, α 2 B, α 2 C receptors. The precise mechanism of action of APOKYN as a treatment for Parkinson's disease is unknown,…
Indications (1)
Clinical Trials (1)
Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment
Started May 2007
117 enrolled
Parkinson's Disease